



MAGNASENSE AB CEO MARCO WITTEVEEN PROVIDES AN UPDATE ON THE STRATEGIC DIRECTION IN NEW VIDEO PRESENTATION

Magnasense AB, a leading innovator in saliva diagnostic solutions, is pleased to announce that Marco Witteveen, the company's CEO, has released a video presentation providing an update on the company's strategic direction. The presentation is now available on the company's official website at www.magnasense.com/investor-relations/presentations/

"We are committed to advancing our capabilities and developing saliva based diagnosis as an alternative to blood tests for identifying systemic disease and other health issues," said Marco Witteveen. "This presentation highlights our strategic priorities and our roadmap for sustainable growth. However, achieving these goals is only possible with the continued support of our current and new investors to fund our progress moving forward."

The video is accessible to stakeholders, investors, and industry professionals who wish to gain a deeper understanding of Magnasense AB's future plans. For more information, visit www.magnasense.com.

For additional information, please contact:

Marco Witteveen, CEO, Magnasense AB

Email: ir@magnasense.com

The Company's Certified Adviser is Eminova Fondkommission AB | adviser@eminova.se

About Magnasense AB

Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.